Queer Eye's Jonathan Van Ness credits GLP-1 medication for 66-pound weight loss
Alongside lifestyle changes, Van Ness credited a GLP-1 medication—commonly used for blood sugar control—as a key factor in his transformation. These medications, including Ozempic, Wegovy, and Mounjaro, have gained popularity for their appetite-suppressing effects. In addition to the medication, Van Ness made significant lifestyle changes, such as reducing alcohol consumption and incorporating group Pilates, which he described as the most impactful shift for both his mental and physical well-being.
The Queer Eye star has previously spoken about his struggles with binge-eating disorder, revealing that he felt 'depressed' and 'out of control' due to compulsive eating habits. In a TikTok video shared in January, he explained that after consulting his doctor, he started GLP-1 injections last September and 'immediately' felt better, describing it as the first time in his life that he felt in control of his food intake.
While many fans praised Van Ness for his transparency, others criticized the use of GLP-1 medications, with some calling him "too skinny." The debate surrounding weight-loss injections continues, with experts such as Columbia University's Dr. Robert Klitzman explaining that these medications work by reducing cravings and slowing digestion. However, he also noted that patients who discontinue GLP-1s often regain weight, as the effects are not permanent.
Van Ness hopes his openness will encourage others to seek help for their health challenges, reinforcing the importance of making informed choices when it comes to wellness.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
1736339786-0%2FUntitled-design-(24)1736339786-0-640x480.webp&w=3840&q=100)
Express Tribune
21 hours ago
- Express Tribune
Jade Thirlwall reveals daily struggle to avoid Ozempic
Little Mix alum Jade Thirlwall is opening up about the ongoing challenges she faces with body image and weight loss pressures. In a recent interview with The Guardian published on August 16, the 32-year-old singer revealed that resisting the use of Ozempic has become a 'daily battle.' 'I don't judge people that do,' Thirlwall explained, 'but because I have a history of eating disorders, I don't know where taking something like that would end for me.' Thirlwall, who previously battled anorexia, noted that social media scrutiny about her body often fuels the pressure. Despite being in what she describes as the 'healthiest' phase of her life, she still encounters comments speculating about her weight or suggesting she may be pregnant whenever she shares photos online. Reflecting on her time with Little Mix, the British star shared that fans once celebrated body empowerment, but some now compare her current appearance to her early 20s when she was struggling with anorexia. She emphasized that her past illness left lasting challenges, but she has worked hard to move forward while pursuing her passion for music. Thirlwall first detailed her experience with anorexia in the group's 2016 memoir Our World, revealing that she began struggling with the condition at 13 before seeking medical help. Today, she continues to advocate for body positivity and hopes to separate her identity as an artist from past struggles. Her candid admission adds to the broader conversation around celebrity use of Ozempic and the pressures of maintaining public image in the entertainment industry.
Express Tribune
a day ago
- Express Tribune
Barbara Palvin opens up about illness and surgery that changed her life
Barbara Palvin has revealed that she recently underwent surgery for endometriosis after silently battling symptoms for years. The Hungarian-born model and actress, who is married to actor Dylan Sprouse, shared the deeply personal update with her followers in a candid Instagram post on 17 August. The 31-year-old admitted she had long assumed that the fatigue, severe cramps and irregular periods she experienced were simply part of her body's natural rhythm. She revealed that for years she endured sleepless nights on the bathroom floor and cancelled plans due to the pain, convinced it was something she simply had to accept. It was only after consulting a specialist that Palvin learned she was suffering from endometriosis, a condition where tissue grows outside the uterus and can cause severe pain, complications and in some cases fertility issues. Although she had attended regular check-ups with her gynaecologist, she explained that the illness often goes undetected in routine exams, leading to years of misdiagnosis or uncertainty for many women. Within three months of seeing a specialist, Palvin underwent surgery to remove the tissue. She said the procedure has already made a noticeable difference, leaving her with more comfortable cycles and renewed hope for her health. Alongside her announcement, she shared photos from her hospital stay, showing both the seriousness of the surgery and her determination to raise awareness. In her message, Palvin encouraged women experiencing similar symptoms to seek medical advice from endometriosis specialists, stressing the importance of early intervention. She wrote that she was grateful she took action and urged others not to ignore their bodies. Palvin ended her post with an optimistic note, saying she was excited for this new chapter and ready to return to work. Her openness has sparked an outpouring of support online, with fans praising her honesty and sharing their own stories of struggling to get diagnosed.
Business Recorder
6 days ago
- Business Recorder
Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk. Lilly said in June it received approval from India's drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device. Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply. The smallest two doses are priced at 14,000 and 17,500 rupees, respectively, and the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses cost 27,500 rupees, the company said. 'If we look at how the highest doses of Mounjaro and Wegovy are priced, it appears (that) Mounjaro's pricing is attractive and competitive,' said Vishal Manchanda from Systematix Institutional Equities. Wegovy's smallest doses of 0.25 mg, 0.5 mg and 1 mg cost 17,345 rupees a month, and its highest doses of 1.7 mg and 2.4 mg cost 24,280 rupees and 26,015 rupees a month, respectively. Lilly began selling Mounjaro in India in late March for diabetes and obesity in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since then, with sales in July doubling month-on-month. The drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
